Janus Henderson Group Ltd. filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 64,540 shares of common stock in Collegium Pharmaceutical, Inc. as of September 30, 2026.
Key Highlights
- Beneficial ownership: Janus Henderson Group Ltd. reported aggregate beneficial ownership of 64,540 shares of Collegium Pharmaceutical, Inc. common stock.
- Percent of class: The 64,540 shares represent 0.2% of the outstanding class, according to the filing.
- Voting and dispositive power: The filing reports 0 shares held with sole voting or sole dispositive power, and 64,540 shares held with shared voting power and shared dispositive power.
- Event date: The date of the event requiring this filing is stated as September 30, 2026.
- Filer classification: Janus Henderson Group Ltd. is identified as a parent holding company (type HC), organized in Jersey, with its principal business office at 201 Bishopsgate, EC2M 3AE, United Kingdom.
- No single managed portfolio exceeds 5%: According to the filing, none of the Managed Portfolios individually own more than five percent of the common stock of Collegium Pharmaceutical, Inc.
Janus Henderson's Amended 13G Filing for Collegium Pharmaceutical
Janus Henderson Group Ltd. submitted Amendment No. 1 to its Schedule 13G on November 16, 2026, covering its beneficial ownership in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) as of the September 30, 2026 event date. The filing was signed by Kristin Mariani, Head of North America Compliance, on behalf of Janus Henderson Group Ltd.
According to the filing, Janus Henderson Group Ltd. is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents, including Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, and several others collectively referred to as the Asset Managers. The filing states that these Asset Managers "generally exercise investment and/or voting discretion on behalf of their clients," which include investment companies, institutional separate accounts, and retail separate accounts, collectively described as Managed Portfolios. As a result of this discretion, the Asset Managers "may be deemed to be the beneficial owner of 64,540 common stock of Collegium Pharmaceutical, Inc."
The filing further notes that the Asset Managers "do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights." The Managed Portfolios, by contrast, hold the right to receive all dividends and sale proceeds. The filing clarifies that it does not include securities, if any, beneficially owned by Janus Henderson Group Ltd.'s ultimate parent, Janus Henderson Group Holdings, LLC, or by any direct or indirect owners of that entity, in accordance with SEC Release No. 34-39538.
What Was Disclosed
Janus Henderson Group Ltd. disclosed, via an amended Schedule 13G, that it beneficially owned 64,540 shares of Collegium Pharmaceutical, Inc. common stock as of September 30, 2026, representing 0.2% of the class, all held with shared voting and shared dispositive power.





Please wait processing your request...